AAV2-hAADC
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aromatic Amino Acid Decarboxylase Deficiency
Conditions
Aromatic Amino Acid Decarboxylase Deficiency
Trial Timeline
Nov 9, 2016 → May 16, 2022
NCT ID
NCT02926066About AAV2-hAADC
AAV2-hAADC is a phase 2 stage product being developed by PTC Therapeutics for Aromatic Amino Acid Decarboxylase Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT02926066. Target conditions include Aromatic Amino Acid Decarboxylase Deficiency.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02926066 | Phase 2 | Completed |
Competing Products
1 competing product in Aromatic Amino Acid Decarboxylase Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| gene therapy | PTC Therapeutics | Phase 1/2 | 38 |